National Cancer Action Center

A coalition of public health organizations, pediatricians and parents today filed a federal lawsuit challenging the Food and Drug Administration’s new enforcement policy that allows e-cigarette and nicotine pouch products to be marketed and sold without the scientific review and marketing authorization required by federal law.

Today, the American Cancer Society and the American Cancer Society Cancer Action Network submitted a comment letter to the Office of Management and Budget strongly opposing a proposed rule that would change the federal government’s grantmaking framework.

Nearly 200 patient advocacy, public health and health care professional organizations sent a letter to the Senate declaring their strong support for the Clinical Trial Modernization Act (S. 4440/H.R. 3521). The bipartisan, bicameral legislation would help remove cost and geographic barriers that keep patients from enrolling and participating in clinical trials. The bill was introduced in the U.S. Senate by Sens. Tim Scott (R-SC) and Mark Warner (D-VA) in April 2026 and in the U.S. House of Representatives in May 2025 by Reps. Raul Ruiz (D-CA) and August Pfluger (R-TX).

WASHINGTON, D.C. – The following is a statement from Lisa Lacasse, president of the American Cancer Society Cancer Action Network: “The FDA’s job is to protect public health, not expand the profit margins of Big Tobacco. Authorizing new modified risk claims for 20 Zyn nicotine products – including flavored